Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.065 CAD | +8.33% |
|
0.00% | -50.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.63 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.00% | 19.47M | - | ||
+29.76% | 5.69B | B- | ||
-32.34% | 3.53B | C+ | ||
-2.23% | 3.06B | C | ||
-25.26% | 2.62B | B- | ||
-10.88% | 2.29B | - | D+ | |
+40.09% | 1.86B | - | ||
+40.90% | 1.43B | - | ||
-15.16% | 1.41B | - | - | |
+42.86% | 1.4B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- DB Stock
- Ratings Decibel Cannabis Company Inc.